3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
4
Completed
3
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma, Follicular
25
Lymphoma, Mantle-Cell
23
Lymphoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Lymphoma, Non-Hodgkin
21
Lymphoma, B-Cell
16
Lymphoma, B-Cell, Marginal Zone
13
Neoplasms
8
Recurrence
7
Waldenstrom Macroglobulinemia
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia
5
Burkitt Lymphoma
5
Neoplasm, Residual
3
Lymphoproliferative Disorders
3
Leukemia, Hairy Cell
3
Hematologic Diseases
3
Myelodysplastic Syndromes
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Biphenotypic, Acute
2
Blast Crisis
2
Sarcoma, Myeloid
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuritis
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myeloid Diseases
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bendamustine Hydrochloride
2
sepantronium
1
acalabrutinib
1
Vincristine
1
Rituximab
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Bone Marrow Transplantation
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphatic Diseases
×
Rituximab
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled